Ticker

Analyst Price Targets — MANE

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
March 2, 2026 8:11 amRoger SongJefferies$75.00$45.85StreetInsider Jefferies Starts Veradermics (MANE) at Buy

Latest News for MANE

Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today reported financial results for the fourth quarter and full year periods ended December 31, 2025, and announced recent corporate and clinical updates. “2025 was a…

Business Wire • Mar 30, 2026
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026.…

Business Wire • Mar 18, 2026
Analysts Set MANE (NYSE:MANE) Target Price at $78.33

Shares of MANE (NYSE: MANE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among

Defense World • Mar 8, 2026
Veradermics to Participate in Upcoming March Investor Conferences

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in…

Business Wire • Mar 3, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for MANE.

No Senate trades found for MANE.

No House trades found for MANE.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top